Peptide library / Digestive & weight / Larazotide
Larazotide
An eight amino acid peptide once tested as an add-on to a gluten-free diet in coeliac disease.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Coeliac disease symptoms despite a gluten-free dietLarge trials
How it is thought to work
Larazotide was designed to tighten junctions between intestinal cells, limiting the leak of gluten fragments that triggers immune activation.
What the evidence shows
Early trials were encouraging, but a phase 3 trial did not reach its main endpoint and development was halted.
Safety and unknowns
It was well tolerated in trials, with side effects similar to placebo.
Regulatory status
Not approved. Development stopped after the phase 3 trial.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
Linaclotide
FDA-approvedA 14 amino acid peptide taken by mouth that acts only inside the gut for irritable bowel syndrome with constipation.
Liraglutide
FDA-approvedA daily GLP-1 receptor agonist, the first of the class approved for chronic weight management.
KPV
Wellness and performanceA three amino acid fragment of alpha-MSH studied for gut and skin inflammation, mostly in animals.
General information, not medical advice. Do not buy or inject unregulated peptides.